Trade Aytu BioScience, Inc. - AYTU CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.072 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023346% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001124% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 0.01 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 1.054 |
| Open | 1.044 |
| 1-Year Change | -60.39% |
| Day's Range | 1.024 - 1.074 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 24, 2025 | 1.054 | 0.000 | 0.00% | 1.054 | 1.054 | 1.004 |
| Apr 23, 2025 | 1.044 | 0.000 | 0.00% | 1.044 | 1.064 | 1.044 |
| Apr 22, 2025 | 1.024 | 0.048 | 4.92% | 0.976 | 1.044 | 0.976 |
| Apr 21, 2025 | 1.014 | 0.057 | 5.96% | 0.957 | 1.024 | 0.957 |
| Apr 17, 2025 | 0.992 | 0.031 | 3.23% | 0.961 | 0.993 | 0.961 |
| Apr 16, 2025 | 1.004 | -0.030 | -2.90% | 1.034 | 1.034 | 0.985 |
| Apr 15, 2025 | 0.994 | -0.010 | -1.00% | 1.004 | 1.024 | 0.970 |
| Apr 14, 2025 | 0.971 | -0.019 | -1.92% | 0.990 | 1.004 | 0.961 |
| Apr 11, 2025 | 0.988 | -0.005 | -0.50% | 0.993 | 1.014 | 0.950 |
| Apr 10, 2025 | 0.990 | -0.064 | -6.07% | 1.054 | 1.054 | 0.990 |
| Apr 9, 2025 | 1.024 | 0.050 | 5.13% | 0.974 | 1.024 | 0.932 |
| Apr 8, 2025 | 0.955 | -0.035 | -3.54% | 0.990 | 1.054 | 0.955 |
| Apr 7, 2025 | 0.984 | 0.080 | 8.85% | 0.904 | 1.014 | 0.902 |
| Apr 4, 2025 | 1.004 | -0.020 | -1.95% | 1.024 | 1.094 | 0.959 |
| Apr 3, 2025 | 1.054 | -0.050 | -4.53% | 1.104 | 1.124 | 1.014 |
| Apr 2, 2025 | 1.134 | -0.020 | -1.73% | 1.154 | 1.154 | 1.134 |
| Apr 1, 2025 | 1.144 | -0.030 | -2.56% | 1.174 | 1.174 | 1.144 |
| Mar 31, 2025 | 1.174 | 0.010 | 0.86% | 1.164 | 1.174 | 1.134 |
| Mar 28, 2025 | 1.164 | -0.010 | -0.85% | 1.174 | 1.214 | 1.164 |
| Mar 27, 2025 | 1.214 | 0.030 | 2.53% | 1.184 | 1.234 | 1.184 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Aytu BioScience, Inc. Company profile
About Aytu Biopharma Inc
Aytu Biopharma, Inc., formerly Aytu BioScience, Inc., is a specialty pharmaceutical company. The Company markets a portfolio of prescription products addressing primary care and pediatric markets. The Company's primary prescription products treat attention deficit hyperactivity disorder (ADHD) and other common pediatric conditions. It markets ADHD products Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets, Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets, and Adzenys-ER (amphetamine) extended-release oral suspension. The Company's other pediatric products include Karbinal ER (carbinoxamine maleate), an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions, and Poly-Vi-Flor and Tri-Vi-Flor, two complementary fluoride-based prescription vitamin product lines containing combinations of fluoride and vitamins in formulations for infants and children with fluoride deficiency.
Financial summary
BRIEF: For the six months ended 31 December 2021, Aytu Biopharma Inc revenues increased 57% to $45M. Net loss increased from $13.8M to $39.4M. Revenues reflect United States segment increase of 69% to $43.7M. Basic Earnings per Share excluding Extraordinary Items decreased from -$1.07 to -$1.53.
Equity composition
Common Stock no Par, 11/11, 30M auth., 4,774,568 issd. Insiders own 66.98%. 06/15, 1-for-12.174, Reverse Stock Split.
| Industry: | Pharmaceuticals (NEC) |
7900 E. Union Avenue
Suite 920
DENVER
COLORADO 80237
US
News
ECB interest-rate forecasts – Projections for the next five years
The European Central Bank (ECB) plays a pivotal role in the economic stability of the eurozone, meaning ECB interest-rate forecasts are key to understanding how financial and economic scenarios might evolve.
14:37, 10 April 2025
BlackRock shareholders: Who owns the most BLK stock?
BlackRock is the leading asset manager in the world – but who are its biggest shareholders? Read on to find out.
13:46, 9 April 2025
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
10:28, 9 April 2025
Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
08:19, 9 April 2025
JasmyCoin price predictions 2025-2030: Third-party price target
How might JASMY behave in the future?
16:13, 8 April 2025
Australian interest-rate projections: where will rates be in 5 years?
As one of the most closely watched economic indicators, Australian interest-rate projections offer valuable insight into the future of the country’s economy.
21:37, 7 April 2025
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025People also watch
Still looking for a broker you can trust?
Join the 720,000+ traders worldwide that chose to trade with Capital.com